Navigation Links
Multiple Vimpat(R) (lacosamide) Studies Presented at American Epilepsy Society Annual Meeting
Date:12/8/2008

R) group and greater than placebo were dizziness (31 percent vs. 8 percent), headache (13 percent vs. 9 percent), nausea (11 percent vs. 4 percent), and diplopia (11 percent vs. 2 percent).

    -- TEAEs were mild to moderate and appeared to be dose-related.

    -- The incidence of weight gain and other troublesome TEAEs such as
       somnolence and cognitive and psychiatric AEs appeared low:

        -- The incidence of somnolence was 7 percent for the Vimpat(R)-treated
           group vs. 5 percent for placebo

        -- The incidence of memory impairment was 2 percent for both Vimpat(R)
           and placebo groups

        -- The incidence of depression was 2 percent for the Vimpat(R)-treated
           group and 1 percent for placebo

        -- The incidence of weight gain was 1 percent for both Vimpat(R) and
           placebo groups

Poster Session 3, December 8, 2008, 11:30 am - 12:30 pm (Poster 3.245)

V. Biton, N. Fountain, F. Rosenow, A. Gil-Nagel, T. Sullivan, D. Hebert, P. Doty

Clinical Trials, Inc., Little Rock, Arkansas; University of Virginia, Charlottesville, Virginia; Philipps-University, Department of Neurology, Marburg, Germany; Hospital Ruber Internacional, Madrid, Spain; SCHWARZ BIOSCIENCES (a member of the UCB Group), Raleigh, North Carolina

Important safety information about Vimpat(R) in the U.S.

Vimpat(R) tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy who are 17 years and older. Vimpat(R) injection is indicated as short-term replacement when oral administration is not feasible in these patients. Patients should be advised that Vimpat(R) may cause dizziness, ataxia, and syncope. Caution is advised for patients with known cardiac conduction problems, who are taking drugs known to induce PR interval prolongation, or with severe cardiac disease. In p
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health to Present Multiple New Studies at 31st Annual San Antonio Breast Cancer Symposium
2. Derma Sciences Announces Multiple Clinical Posters Featuring MEDIHONEY(R) and ALGICELL Ag(R) to be Presented at Upcoming Wound Care Conference
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. Senescos Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
5. Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug
6. Environmental Tectonics Corporation Announces a Multiple Sale of Hyperbaric Monoplace Chambers to Comprehensive Healthcare Solutions
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting
10. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
11. Environmental Tectonics Corporation Announces a Multiple Sale for Monoplace Hyperbaric Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... October 20, 2014 The report ... Dispensing Systems, Packaging and Labeling Systems, Table-top Counters) ... - Global Forecasts & Trends to 2019” analyzes ... opportunities in North America, Europe, Asia-Pacific, and the ... market tables and 30 figures spread through 300 ...
(Date:10/20/2014)... Convey Computer , the leader in ... State University won first place in the 2014 ... the team’s solution achieved the highest overall performance in ... place finisher. , Experts from all segments of the ... challenge, using a variety of design tools, hardware and ...
(Date:10/20/2014)... , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... million which brings Q3 orders to $5.8 million and provides a ... projects in North America and one in ... to bid new projects at record levels," said Peter Bruijns ... higher at the end of Q3 than they have been for ...
(Date:10/20/2014)... 2014  GenVec, Inc. (NASDAQ: GNVC ) today ... from its board of directors effective on October 24, 2014.  ... served as its chairman from June 2006 to November 2013.  ... Corporate Governance and Audit Committees of the board.  ... of dedicated service to GenVec, and its stockholders," said ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3Zola P. Horovitz To Retire From GenVec Board 2
... July 8 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics,Inc. (OTC Bulletin ... firm specializing in the manufacture, research, development,marketing ... Dr.,Shuguang Fang, China-Biotics, Chief Technology Officer, has ... China,s 3rd Annual Food Safety Technology Forum,2008 ...
... purchase, distribute US-made bulk API, BATON ... Albemarle Corporation (NYSE: ALB ), a ... and other active pharmaceutical,ingredients (APIs), has signed ... Laboratories Ltd. As per the agreement, effective,immediately, ...
... Board and Management Focused on Near-Term Milestones and Maintain ... ... DIEGO, July 8 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI, OTC: MGIFF), ... requisition for a special meeting of shareholders,for the purpose of ...
Cached Biology Technology:China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 2China-Biotics, Inc. to Present at China's 3rd Annual Food Safety Technology Forum 2008 3Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 2Albemarle Enters Ibuprofen Agreement with Dr. Reddy's 3MIGENIX Corporate Update and Requisition of Special Meeting 2MIGENIX Corporate Update and Requisition of Special Meeting 3MIGENIX Corporate Update and Requisition of Special Meeting 4MIGENIX Corporate Update and Requisition of Special Meeting 5MIGENIX Corporate Update and Requisition of Special Meeting 6MIGENIX Corporate Update and Requisition of Special Meeting 7MIGENIX Corporate Update and Requisition of Special Meeting 8
(Date:10/18/2014)... for evaluation of suspected genetic conditions, whole-exome sequencing ... including detection of a number of rare genetic ... to a study appearing in JAMA . ... the American Society of Human Genetics annual meeting. ... regions of thousands of genes simultaneously using next-generation ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... the possibility that the critically short supply of livers ... "marginal" livers with a substance that protects them from ... report appears in ACS, journal Molecular Pharmaceutics . ... for liver transplants has grown over the years, though ...
... DALLAS June 1, 2011 A drug ... as a therapy for a common form of dementia, ... hydroxamic acid (SAHA) holds promise as a first-generation drug ... (FTD), a progressive, inherited neurodegenerative disease for which there ...
... Virginia Tech,s Advanced Experimental Thermofluid Engineering Research ... professor Pavlos P. Vlachos, professor of mechanical engineering, ... mechanics from the Measurement Science and Technology ... Physics. John J. Charonko, of Blacksburg, ...
Cached Biology News:Cancer drug holds promise as first treatment for common, inherited dementia 2Virginia Tech mechanical engineers win measurement science best paper award 2
...
... Signet offers the most comprehensive, cost-effective ... We have incorporated unprecedented quality into ... This includes proven detection chemistries and ... the TechMate protocol. It also includes ...
... Resistant (X/R) Red System consists of ... Activator and X/R Red Buffer. The ... phosphatase to produce red staining that ... Contains:, , Buffer, 100 mL , ...
Human Cell Line Slides...
Biology Products: